Contineum Therapeutics (CTNM) EBIT Margin (2023)
Contineum Therapeutics' EBIT Margin history spans 1 years, with the latest figure at 77.87% for Q2 2023.
- Quarterly EBIT Margin changed N/A to 77.87% in Q2 2023 from the year-ago period, while the trailing twelve-month figure was 99.62% through Jun 2024, changed N/A year-over-year, with the annual reading at 9.77% for FY2023, N/A changed from the prior year.
- EBIT Margin came in at 77.87% for Q2 2023.
- In the past five years, EBIT Margin ranged from a high of 77.87% in Q2 2023 to a low of 77.87% in Q2 2023.